Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2492 • 2016 ACR/ARHP Annual Meeting
Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Peter C. Taylor¹, Rieke Alten², Juan Jesus Gomez-Reino³, Roberto Caporali⁴, Philippe Bertin⁵, Laura Grant⁶, Elaine Brohan⁶, Jane Wells⁶, Radu Vasilescu⁷ and Miriam Tarallo⁸, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Charité University Medicine, Berlin, Germany, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Università di Pavia, Pavia, Italy, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Values, Bollington, United Kingdom, ⁷Medical Affairs, Pfizer, Brussels, Belgium, ⁸GHV, Pfizer, Rome, Italy
Background/Purpose: The high prevalence and significant burden of RA has led to the development of a wide variety of treatments; specifically, conventional synthetic DMARDs, and…
Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Julio Ramírez¹, Andrea Cuervo², Jose Antonio Narváez³, Virginia Ruiz-Esquide², Javier Hernández-Gañán³, Raquel Celis⁴, Jose Inciarte-Mundo², M. Victoria Hernández², Jose L. Pablos⁵, Raimon Sanmarti² and Juan D. Cañete², ¹Rheumatology, Hospital Clínic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Radiology, Hospital Bellvitge, Barcelona, Spain, ⁴Rheumatology, Arthritis Unit, Barcelona, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…
Abstract Number: 1566 • 2016 ACR/ARHP Annual Meeting
Histone Lysine Methylation and STAT3 Differentially Regulate Constitutive and IL-6-Induced MMPs Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^2,3, Yoshimi Aizaki^1,2, Kazuhiro Yokota¹, Hiroshi Kajiyama¹, Yu Funakubo Asanuma¹, Kojiro Sato¹, Hiromi Oda⁴ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ⁴Orthopedic Surgery, Faculty of Medicine, Saitama Medical Univeristy, Morohongo Moroyama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes progressive joint destruction. In spite of the modern medications, including biologic reagents, it…
Abstract Number: 2503 • 2016 ACR/ARHP Annual Meeting
Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
Iris Navarro-Millán¹, Ronan O'Beirne², Melanie Morris³, Bernadette Johnson¹, James Willig⁴, Huifeng Yun⁵, Andrea Cherrington⁶, Liana Fraenkel⁷, Monika M. Safford⁸ and Jeffrey Curtis⁹, ¹Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Continuing Medical Education, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Yale University School of Medicine, New Haven, CT, ⁸Weill Cornell Medical College, New York, NY, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Little is known on what subjective or objective data that rheumatologists consider most important for them to inform their treatment decisions for patients…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Joel M. Kremer¹, Edward C. Keystone², Paul Emery³, Heidi S. Camp⁴, Alan Friedman⁴, Li Wang⁴, Ahmed A. Othman⁴, Nasser Khan⁴ and Steven Jungerwirth⁴, ¹Albany Medical College, Albany, NY, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 1529 • 2015 ACR/ARHP Annual Meeting
Trabecular Bone Score in Early Rheumatoid Arthritis
Eulalia Armengol¹, Helena Borrell Paños¹, Joan Miquel Nolla¹, Javier Narváez² and Carmen Gomez Vaquero¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is associated with low bone mass and increased risk of fragility fractures that are related to patient characteristics, treatments and disease…
Abstract Number: 2588 • 2015 ACR/ARHP Annual Meeting
Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women
Minna Turkkila¹, Apostolos Bossios², Malin Erlandsson³, Karin ME Andersson³, Sofia Töyrä Silfverswärd⁴, Maria Rolf⁵, Linda Ekerljung², Carina Malmhäll², Bo Lundbäck² and Maria Bokarewa⁶, ¹University of Göteborg, Göteborg, Sweden, ²The Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology and Inflammation Research, Gothenburg University, Gothenburg, Sweden, ⁵Department of Rheumatology and Inflammation Research University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose : Patients with rheumatoid arthritis (RA) are predominantly female, smokers and positive for autoantibodies, rheumatoid factor and antibodies to citrullinated peptides. The oncoprotein survivin…
Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
julien henry¹, stéphane pavy², Jacques Gottenberg³, rakiba belkhir⁴, Stéphanie Rouanet⁵, Jérémie Sellam⁶, Xavier Mariette⁷ and raphaèle seror⁴, ¹departement of rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ³Hautepierre, Strasbourg, France, ⁴Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁵Biostatistics, Roche France, Boulogne-Billancourt, France, ⁶Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁷Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…
Abstract Number: 435 • 2015 ACR/ARHP Annual Meeting
Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)
Vibeke Strand¹, Mark Kosinski², Neil Graham³, Chieh-I Chen³, George J. Joseph⁴, Deborah Bauer⁵, Yong Lin⁵, Cesar Pacheco-Tena⁶ and Roy Fleischmann⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²QualityMetric Inc, Lincoln, RI, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose : Sarilumab, a human monoclonal antibody directed against the IL-6 receptor, in combination with non-biologic DMARDs, demonstrated efficacy in the TARGET RCT (NCT01709578). TEAEs…
Abstract Number: 1543 • 2015 ACR/ARHP Annual Meeting
Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Tomas Cazenave¹, Natalia Zamora¹, Gustavo Citera^1,2 and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
Background/Purpose: An increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). Adequate stratification of the CV risk is an…
Abstract Number: 2591 • 2015 ACR/ARHP Annual Meeting
Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Pascal Zufferey¹, Myriam Riek², Giorgio Tamborrini³, Laure Brulhart⁴, Martin Toniolo⁵, Sandra Blumhardt⁶, Burkhard Moeller^7,8 and Hans Ruedi Ziswiler⁹, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³Rheumatologie, Bethesda spital, Basel, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁸Rheumatology, Inselspital University Hospital, Bern, Switzerland, ⁹Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as…
Abstract Number: 437 • 2015 ACR/ARHP Annual Meeting
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Tanja Schjødt Jørgensen¹, Carl Turesson², Meliha C. Kapetanovic³, Martin Englund^4,5, Aleksandra Turkiewicz⁴, Robin Christensen¹, Henning Bliddal¹, Pierre Geborek³ and Lars Erik Kristensen¹, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology Lund University and Skåne University Hospital, Lund, Sweden, ⁴Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: About 30% of patients receiving biologic therapy do not have concomitant conventional synthetic DMARDs (csDMARDs). Little is known about the role of different mode…
Abstract Number: 1552 • 2015 ACR/ARHP Annual Meeting
Illness Perceptions in Rheumatoid Arthritis: A Comparison of Canadian and Nigerian Patients
Susan J. Bartlett¹, Olufemi Adelowo², Maria Celia Bazan Bardales³ and Ines Colmegna⁴, ¹Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Arthrimed Specialist Clinic, Lagos, Nigeria, ³Rheumatology, McGill University, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada
Background/Purpose: Illness perceptions (IP) are the beliefs and expectations that an individual has about medical conditions. IP cluster around five coherent themes and provide a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].